| Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979) |
|---|
| 01/10/2008 | WO2008004245A1 Process for the preparation of optically pure or optically enriched enantiomers of sulphoxide compounds |
| 01/10/2008 | WO2008004117A1 Selective azole pde10a inhibitor compounds |
| 01/10/2008 | WO2008004096A1 Pyrazole derivatives as cytochrome p450 inhibitors |
| 01/10/2008 | WO2008003770A1 Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumor agents |
| 01/10/2008 | WO2008003746A1 N-(4-pyridin-2-ylbutyl) carboxamide derivatives, their process of preparation and their use as fungicides |
| 01/10/2008 | WO2008003741A1 N- [ (pyridin- 2 -yl) methoxy]heterocyclyl carboxamide derivatives and related compounds as fungicides |
| 01/10/2008 | WO2008003703A1 Indoles as 5-ht6 modulators |
| 01/10/2008 | WO2008003697A1 Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
| 01/10/2008 | WO2008003665A1 Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group |
| 01/10/2008 | WO2008003412A1 The use of 1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension |
| 01/10/2008 | WO2007131982A3 Substituted prolinamides, production thereof and their use as drugs |
| 01/10/2008 | WO2007131764A3 New heterocyclic compounds for the inhibition of integrins and use thereof |
| 01/10/2008 | WO2007123855A3 Pyrazolines for controlling invertebrate pests |
| 01/10/2008 | WO2007123853A3 Five-membered heterocyclic invertebrate pest control agents |
| 01/10/2008 | WO2007116313A3 Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
| 01/10/2008 | WO2007104652A3 Non-peptidic renin inhibitors nitroderivatives |
| 01/10/2008 | WO2007050425A3 Lxr modulators |
| 01/10/2008 | WO2007021803A8 Compounds for the treatment of inflammatory disorders |
| 01/10/2008 | WO2007006922A8 Novel 1h-indole-pyridinecarboxamide derivatives and 1h-indole-piperidinecarboxamide and their use as hydroxylase tyrosine inducers |
| 01/10/2008 | US20080009628 One-Pot Condensation-Reduction Methods for Preparing Substituted Allylic Alcohols |
| 01/10/2008 | US20080009625 6,13-bis(triisopropylsilylethynyl)pentacene, use in in various electronic devices and in a formulation for ink jet printing and in an organic field effect transistors |
| 01/10/2008 | US20080009527 Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas |
| 01/10/2008 | US20080009520 Benzimidazolidinone derivatives as muscarinic agents |
| 01/10/2008 | US20080009506 Imidazole Compound |
| 01/10/2008 | US20080009498 Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use |
| 01/10/2008 | US20080009495 Compound Containing Basic Group and Use Thereof |
| 01/10/2008 | US20080009494 Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses |
| 01/10/2008 | US20080009493 Substituted Benzimidazoles and Imidazo-[4,5]-Pyridines |
| 01/10/2008 | US20080009488 protein kinase inhibitors such as Methyl {5-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate, used to modulate cellular activities such as proliferation, differentiation, apoptosis, migration and chemoinvasion |
| 01/10/2008 | US20080009479 Tetrahydrobenzazepines as Histamine H3 Receptor Ligands |
| 01/10/2008 | US20080008708 Tyrosine kinase inhibitors |
| 01/10/2008 | CA2660031A1 Pyrazole derivatives as cytochrome p450 inhibitors |
| 01/10/2008 | CA2656623A1 Modulators of metabolism and the treatment of disorders related thereto |
| 01/10/2008 | CA2656622A1 Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| 01/10/2008 | CA2656618A1 Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| 01/10/2008 | CA2656617A1 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof |
| 01/10/2008 | CA2656520A1 Modulators of metabolism and the treatment of disorders related thereto |
| 01/10/2008 | CA2656398A1 Substituted piperidines that increase p53 activity and the uses thereof |
| 01/10/2008 | CA2656307A1 Use of 1,4-diaryldihydropyrimidin-2-one derivatives for the treatment of pulmonary arterial hypertension |
| 01/10/2008 | CA2655694A1 1,4-substituted indoles useful for modulation of the 5-ht6 receptor |
| 01/10/2008 | CA2655675A1 Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
| 01/10/2008 | CA2655633A1 New pyridine analogues |
| 01/10/2008 | CA2655629A1 New pyridine analogues |
| 01/10/2008 | CA2655628A1 New pyridine analogues |
| 01/10/2008 | CA2654246A1 Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group |
| 01/09/2008 | EP1876178A1 Cyanopyridine derivative and use thereof as medicine |
| 01/09/2008 | EP1876174A1 Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors |
| 01/09/2008 | EP1875925A1 Preventive or remedy for bowel disease |
| 01/09/2008 | EP1874770A1 Phenylacetamides suitable as protein kinase inhibitors |
| 01/09/2008 | EP1874760A1 (lh-ind0l-7-yl)-( (pyrimidin-2 -yl-amino) methanone derivatives and related compounds as igf-rl inhibitors for treating cancer |
| 01/09/2008 | EP1874758A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| 01/09/2008 | EP1874757A1 Vla-4 antagonists |
| 01/09/2008 | EP1874756A1 Chromane and chromene derivatives and uses thereof |
| 01/09/2008 | EP1874746A2 Novel histamine h3-receptor ligands and their therapeutic applications |
| 01/09/2008 | EP1874739A1 Pharmaceutically active diazepanes |
| 01/09/2008 | EP1874734A1 1h-imidiazole derivatives as cannabinoid cb2 receptor modulators |
| 01/09/2008 | EP1874315A2 Compositions of novel opioid compounds and method of use thereof |
| 01/09/2008 | EP1874303A1 Pyrazole compounds as prostaglandin receptors ligands |
| 01/09/2008 | EP1874299A2 Vla-4 antagonists |
| 01/09/2008 | EP1711473B1 Substituted n-cyclohexylimidazolinones having an mch-modulatory effect |
| 01/09/2008 | EP1638934B1 3-aminopyrrolidines as inhibitors of monoamine uptake |
| 01/09/2008 | EP1620409B1 Quinoxalin-3-one derivatives as orexin receptor antagonists |
| 01/09/2008 | EP1400513B1 Unsymmetrical cyclic diamine compound |
| 01/09/2008 | EP1385845B1 N-aroyl cyclic amines |
| 01/09/2008 | EP1373218B1 Imidazolyl derivatives useful as histamine h3 receptor ligands |
| 01/09/2008 | EP1239877B1 Composition comprising a tnf-alpha inhibitor and an integrin alphavbeta3 receptor antagonist |
| 01/09/2008 | EP1176956B1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 01/09/2008 | CN101103077A Anthrapyridone compound, magenta ink composition and colored matter |
| 01/09/2008 | CN101103028A Heteroaryl substituted quinolin-4-ylamine analogues |
| 01/09/2008 | CN101103026A Bicyclic heteroaryl derivatives for treating viruses |
| 01/09/2008 | CN101103022A New carboxylic acid amide used as XA inhititor |
| 01/09/2008 | CN101103020A Cgrp受体拮抗剂 Cgrp receptor antagonists |
| 01/09/2008 | CN101103019A 2-(cyclic aminocarbonyl)indoline derivative and medicinal composition containing the same |
| 01/09/2008 | CN101103018A Compounds for the treatment of CNS and amyloid associated diseases |
| 01/09/2008 | CN101103017A Novel aminopyridine derivatives having Aurora-A selective inhibitory action |
| 01/09/2008 | CN101103016A Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same |
| 01/09/2008 | CN101103015A 5-thioxo-1,5-dihydro-2h-pyrrol-2-one derivatives as liver X receptor modulators |
| 01/09/2008 | CN101103014A N-heterocyclyl phthalic acid diamides as insecticides |
| 01/09/2008 | CN101103005A Quinazoline derivatives, preparation methods and uses thereof |
| 01/09/2008 | CN101103004A Novel cis-imidazolines |
| 01/09/2008 | CN101103002A 3,4,(5)-substituted tetrahydropyridines |
| 01/09/2008 | CN101102773A Aminopyrazine analogs for treating glaucoma and other RHO kinase-mediated diseases |
| 01/09/2008 | CN101100467A Piperidinopyrazoles compound and its preparation method and application |
| 01/09/2008 | CN101100466A Non-reversible protein tyrosine phosphorus acylase inhibitor and its preparation and application |
| 01/09/2008 | CN101100465A Cation carbazole compound and application for the same as biphoton nucleic acid fluorescent probe |
| 01/09/2008 | CN101099740A Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same |
| 01/09/2008 | CN100360522C Novel compounds having selective inhibiting effect at GSK3 |
| 01/09/2008 | CN100360521C 4,4-disubstituted piperidine derivatives having CCR3 antagonism |
| 01/09/2008 | CN100360520C Synthesis of 4-(piperidyl)(2-pyridy)methanone-(e)-o-methyloxime and its salts |
| 01/09/2008 | CN100360507C Inhibition of raf kinase using substituted heterocyclic ureas |
| 01/09/2008 | CN100360505C Quinazoline derivatives as angiogenesis inhibitors |
| 01/09/2008 | CN100360130C 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists |
| 01/08/2008 | US7317103 Imaging agents for diagnosis of Parkinson's disease |
| 01/08/2008 | US7317102 Diarylmethyl and related compounds |
| 01/08/2008 | US7317032 Imidazolyl inhibitors of 15-lipoxygenase |
| 01/08/2008 | US7317031 3-(SO2-substituted anilino)-5-amino-1-((hetero)aryl-carbonyl- or sulfonyl)-1H-1,2,4-triazoles: 4-[[5-amino-1-[(3-methyl-2-thienyl)carbonyl]-1H-1,2,4-triazol-3-yl]amino]-benzenesulfonamide; for treating melanoma; cervical, ovarian and prostate adenocarcinoma; colon carcinoma and breast cancer |
| 01/08/2008 | US7317028 Antitumor agents; autoimmune disease; skin disorders; anticancer agents |
| 01/08/2008 | US7317027 Azaindole-derivatives as factor Xa inhibitors |
| 01/08/2008 | US7317025 Non-peptidic NPY Y2 receptor inhibitors |
| 01/08/2008 | US7317022 3-isopropyl-2-oxo-2,3-dihydrobenzoimidazole-1-carboxylic acid [(1S,3R,5R)-8-((S)-2-hydroxy-3-methylamino-propyl)-8-azabicyclo[3.2.1]oct-3-yl]-amide; bioavailability upon oral administration; medical conditions mediated by 5-HT4 receptor activity |